Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and solid tumours that depend on BCR‑ABL, c‑KIT or PDGFR signaling. GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets malignant cells driven by specific tyrosine‑kinase pathways and is used in several approved oncologic indications. - Chronic myeloid leukemia (CML): reduces proliferation of BCR‑ABL‑positive leukemic cells and improves long‑term survival. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT‑driven tumor growth and helps achieve disease control. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides targeted inhibition of BCR‑ABL to achieve remission in eligible patients.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Peripheral edema - Muscle cramps or pain - Fatigue - Diarrhoea - Skin rash

Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Anaphylaxis or severe hypersensitivity reactions

Patients should be monitored closely for laboratory and clinical changes that may require dose adjustment or temporary discontinuation. - Blood counts: monitor complete blood count regularly to detect cytopenias. - Liver function: assess hepatic enzymes before initiation and periodically during therapy. - Cardiac health: avoid in patients with pre‑existing severe heart failure. - Renal function: use caution and adjust dose in moderate to severe renal impairment. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering plasma levels. - Concomitant use with potent P‑glycoprotein inhibitors can raise systemic concentrations.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Anticoagulants such as warfarin: imatinib can alter INR, necessitating closer monitoring. - Diuretics (e.g., furosemide): may exacerbate fluid retention; monitor for edema.